Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna Stock Falls After Vaccine Maker's Wider-Than-Expected Loss
Moderna shares fell after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2.91 per share, ...
Earnings call transcript: Moderna Q4 2024 sees revenue drop, market reacts
Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...
Moderna Stock Falls After Vaccine Maker Posts Wider-Than-Expected Loss
Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...
2MRNA : Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Hosted on MSN7h
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
Moderna stock down pre-market on mixed 2024 earnings
Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.